


CIBMTR's mission is to lead transformative and collaborative research to improve outcomes in cellular therapy.

CIBMTR strategy is organized into 4 pillars:



ASH ABSTRACTS: Saturday, December 6, 2025

Title	Status	Time(ET)/Session	Presenter
Superior long-term outcomes with fludarabine and melphalan reduced-intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data	Oral	9:30 AM - 11:00 AM Presentation: 9:30 AM Session: 721	Piyanuch Kongtim
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real world: A CIBMTR analysis	Oral	9:30 AM - 11:00 AM Presentation: 9:30 AM Session: 907	Hira Mian
Reduced-intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507	Oral	12:00 PM - 1:30 PM Presentation: 12:15 PM Session: 721	Mark Walters
Effect of <i>FLT3</i> maintenance in older <i>FLT3-ITD</i> + adults undergoing allogeneic HCT: A post-hoc analysis of BMT CTN 1506	Oral	12:00 PM - 1:30 PM Presentation: 12:15 PM Session: 723	Sameem Abedin
Longer telomeres in donors aged ≥ 35 years reduce graft failure and non-relapse mortality after allogeneic HCT	Oral	4:00 PM - 5:30 PM Presentation: 4:00 PM Session: 721	Nico Gagelmann
Impact of HLA alloimmunization on availability of HLA well-matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation	Poster	5:30 PM - 7:30 PM Session: 721	Brian Shaffer
Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies	Poster	5:30 PM - 7:30 PM Session: 721	Filippo Milano
Predicting donor engraftment success in adults post haploidentical bone marrow transplant for sickle cell disease	Poster	5:30 PM - 7:30 PM Session: 722	Joshree Shrestha

ASH ABSTRACTS: Sunday, December 7, 2025

Title	Status	Time(ET)/Session	Presenter
The MEASURE Genome Atlas: Acute myeloid leukemia at diagnosis and complete remission	Oral	9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 618	Kai Yu
Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR	Oral	4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 907	Muhammad Bilal Abid
Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) study	Poster	6:00 PM - 8:00 PM Session: 721	Kirsten Williams

continued on next page ...

Title	Status	Time(ET) /Session	Presenter
Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)	Poster	6:00 PM - 8:00 PM Session: 623	Amer Beitinjane
Phase II study of post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced-intensity conditioning: Results from the NMDP-sponsored ACCESS expansion study	Poster	6:00 PM - 8:00 PM Session: 722	Mahasweta Gooptu

ASH ABSTRACTS: Monday, December 8, 2025

Title	Status	Time(ET) /Session	Presenter
Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and Tac/MTX GVHD prophylaxis: Results from the BMT CTN 1801 study	Oral	10:30 AM - 12:00 PM Presentation: 10:45 AM Session: 722	Steven Siegel
Post-transplant cyclophosphamide-based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants	Oral	2:45 PM - 4:15 PM Presentation: 2:45 PM Session: 722	Pashna Munshi
CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH)—a matched cohort analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR) and the AIDS Malignancy Consortium (AMC)	Oral	2:45 PM - 4:15 PM Presentation: 2:45 PM Session: 906	Stefan Barta
Reduced chronic graft-versus-host disease after allogeneic HSCT with cryopreserved peripheral blood stem cell grafts: A CIBMTR analysis	Oral	2:45 PM - 4:15 PM Presentation: 3:15 PM Session: 722	Alexandria Maurer
Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP-sponsored ACCESS study	Oral	2:45 PM - 4:15 PM Presentation: 4:00 PM Session: 722	A. Jimenez Jimenez
Long-term survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis	Oral	4:30 PM - 6:00 PM Presentation: 4:30 PM Session: 723	Elizabeth Stenger
V52 unconventional T cells in the donor graft are associated with improved overall survival after unrelated donor alloHCT for AML and MDS: An analysis from the DKMS and NMDP graft composition study	Oral	4:30 PM - 6:00 PM Presentation: 4:30 PM Session: 732	Kate Markey
Post hoc analysis from BMT CTN 1506: Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib	Oral	4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 732	Mark Levis
Acute myeloid leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study	Oral	4:30 PM - 6:00 PM Presentation: 5:15 PM Session: 732	Alexandra Gomez-Arteaga
Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel	Poster	6:00 PM - 8:00 PM Session: 623	Aung Tun
Outcomes of HLA-matched unrelated versus haploidentical hematopoietic cell transplantation in acute leukemia: A multicenter observational study in Brazil facilitated by the CIBMTR	Poster	6:00 PM - 8:00 PM Session: 721	Mariana Kerbaui
ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation	Poster	6:00 PM - 8:00 PM Session: 723	Stephen Spellman
Living the recovery: One-year QOL outcomes for patients receiving PTCy GVHD prophylaxis on the ACCESS clinical trial	Poster	6:00 PM - 8:00 PM Session: 723	Rachel Cusatis
Real-world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease-positive B-cell acute lymphoblastic leukemia: A CIBMTR database analysis	Poster	6:00 PM - 8:00 PM Session: 723	Wael Saber
An implementation science approach to optimize adoption of hematopoietic cell transplant survivorship care plans	Poster	6:00 PM - 8:00 PM Session: 901	Dekozlymn Anderson
The feasibility of collecting social determinants of health in the national multicenter GRASP sickle cell gene therapy trial	Poster	6:00 PM - 8:00 PM Session: 904	Colleen Kelly